ArticleThorax2020
Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study.
Article in Thorax, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 125 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rehabilitation of People With Post-tuberculosis Lung Disease
The Feasibility and Acceptability of a Diagnostic Algorithm for Timely Post-tuberculosis Lung Disease Diagnosis at Primary Health Care Facilities in Mbarara, Uganda.
Who cites it
125 citing papers in PubMed, 6 syntheses or guidelines pooled it, 198 citations in OpenAlex.
- Multimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis.BMJ global health · 2026Pooled it
- Factors associated with severity of pulmonary tuberculosis in people living with and without HIV: a systematic review.BMC infectious diseases · 2026Pooled it
- Prevalence and associated factors of post-tuberculosis lung disease in Sub-Saharan Africa: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2025Pooled it
- Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Systematic review on the use of patient-held health records in low-income and middle-income countries.BMJ open · 2021Pooled it
- Clinical and cost effectiveness of pulmonary rehabilitation for people with post-tuberculosis lung disease in Kyrgyzstan: a single-blind randomized controlled trial.Annals of the American Thoracic Society · 2026Trial
- Clinical and radiographic characteristics of presumptive tuberculosis patients previously treated for tuberculosis in Zambia.PloS one · 2022Trial
- Doxycycline host-directed therapy in human pulmonary tuberculosis.The Journal of clinical investigation · 2021Trial
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Persistent respiratory, psychological and quality-of-life impairments 2 years post-tuberculosis: evidence from a cohort study in Cambodia.The European respiratory journal · 2026Article
- Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis.American journal of respiratory and critical care medicine · 2026Article
- Association Between Physical Function, Pulmonary Function, and Social Determinants of Health in Individuals with Post-Tuberculosis Lung Disease.Advances in respiratory medicine · 2026Article
- Beyond Cure: A Scoping Review of Post-Tuberculosis Long-Term Health Outcomes.Tropical medicine and infectious disease · 2026Review
- ITARA research programme: Investigating Integrated Tuberculosis And Respiratory care in Africa using transdisciplinary methods.BMJ open · 2026Article
- Tuberculosis and Post-Tuberculosis Lung Changes Are Associated with Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study.Journal of personalized medicine · 2026Article
- Lung function impairment at pulmonary TB and HIV/TB diagnosis: a South African cross-sectional cohort analysis.BMJ open respiratory research · 2026Article
- Systemic Gaps and Roadmap for Integrated Care for Post-tuberculosis Lung Disease in Ethiopia: A Narrative Review.Cureus · 2026Review
- Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults.American journal of respiratory and critical care medicine · 2026Observational
- High prevalence of persistent tuberculosis-related symptoms 6 months after treatment in pulmonary tuberculosis.BMJ open respiratory research · 2026Observational
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundPost-tuberculosis lung damage (PTLD) is a recognised consequence of pulmonary TB (pTB). However, little is known about its prevalence, patterns and associated outcomes, especially in sub-Saharan Africa and HIV-positive adults.
methodsAdult (≥15 years) survivors of a first episode of pTB in Blantyre, Malawi, completed the St George's Respiratory Questionnaire, 6-minute walk test, spirometry and high-resolution CT (HRCT) chest imaging at TB treatment completion. Symptom, spirometry, health seeking, TB-retreatment and mortality data were collected prospectively to 1 year. Risk factors for persistent symptoms, pulmonary function decline and respiratory-related health-seeking were identified through multivariable regression modelling.
resultsBetween February 2016 and April 2017, 405 participants were recruited. Median age was 35 years (IQR: 28 to 41), 77.3% (313/405) had had microbiologically proven pTB, and 60.3% (244/403) were HIV-positive. At pTB treatment completion, 60.7% (246/405) reported respiratory symptoms, 34.2% (125/365) had abnormal spirometry, 44.2% (170/385) had bronchiectasis ≥1 lobe and 9.4% (36/385) had ≥1 destroyed lobe on HRCT imaging. At 1 year, 30.7% (113/368) reported respiratory symptoms, 19.3% (59/305) and 14.1% (43/305) of patients had experienced declines in FEV
conclusionsPTLD is a common and under-recognised consequence of pTB that is disabling for patients and associated with adverse outcomes beyond pTB treatment completion. Increased efforts to prevent PTLD and guidelines for management of established disease are urgently needed. Low-cost clinical interventions to improve patient outcomes must be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.